News / Social Media
December 2025
EU Cancer Mission Conference in Copenhagen, Denmark
“Advancing cancer care: Focus on personalized treatment and innovation for all Europeans”
Prof. Dr. Dr. Harald Mischak will give a presentation at the EU Cancer Mission Conference on December 4, 2025, as part of the MULTIR project on personalized tumor therapy.
For further information, please refer to the program.
October 2025
New urine test enables more precise long-COVID diagnosis – protexam provides key technology
An international research team has achieved a significant breakthrough in Long COVID research, with the active involvement of protexam. Together with clinical partners as part of the EU-funded UriCoV project, they have developed a novel, non-invasive urine test capable of detecting Long COVID at the molecular level. The approach analyzes tiny protein fragments (peptides) in urine and, for the first time, provides an objective, measurable basis for diagnosing the so-called Post-Acute COVID Syndrome (PASC).
Precise diagnosis through proteomic analysis
As part of the study, urine samples from 100 individuals were analyzed — 50 patients with Long COVID whose infection had occurred around ten months earlier, and 50 control subjects without any post-COVID conditions. Using the proteome analysis developed by protexam, 195 peptides were identified that were significantly altered in individuals affected by Long COVID.
This peptide combination — referred to as PASC195 — formed the basis for a computer-assisted diagnostic model that was able to identify Long COVID cases with an accuracy of over 95 percent. This makes the method the first objective, biological tool capable of distinguishing Long COVID from similar conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
New insights into the disease mechanisms
Many of the altered peptides originate from collagen alpha chains, an important component of connective tissue. This suggests that Long COVID is associated with disruptions in collagen regulation, persistent inflammation, and vascular damage.
In addition, in silico analyses showed that certain medications — including GLP-1 receptor agonists and mineralocorticoid receptor antagonists — may represent effective therapeutic approaches for Long COVID.
“Our technology reveals what was previously hidden,” says Prof. Harald Mischak, CEO of protexam. “With urine peptide analysis, we can not only diagnose Long COVID but also tailor the appropriate medications to the patient’s individual proteome.”
Innovation for personalized medicine
Through the use of its innovative proteome analysis, protexam makes a significant contribution to deciphering complex disease mechanisms and opening new avenues in personalized medicine.
With the new urine test, Long COVID diagnostics could become faster, more accurate, and more patient-friendly — providing both affected individuals and treating physicians with much-needed clarity about the condition. protexam is working to make this test available as an in vitro diagnostic (IVD).
You can find the original study here.
June 2025
AGI and proteome analysis: The molecular symbiosis of diagnostics and therapy
The integration of Artificial General Intelligence (AGI) in the proteomic analysis This opens up new dimensions for understanding pathophysiological processes and developing individualized therapy concepts. This connection represents a Paradigm shift in biomedical research and has the potential to fundamentally transform medical knowledge acquisition and clinical decision-making processes.
The modern Proteome analysis enables the identification and quantification of over 12,000 disease-specific proteins as well as a large number of their Peptide fragmentsThese high-resolution molecular data provide detailed information about the functional manifestation of a disease – both at the level of general patterns and in its specific form. individual molecular signature.
By applying AGI-supported analysis methods These complex datasets can be correlated at an unprecedented depth. The AGI recognizes Patterns, interactions, and causal relationships between different disease processes and enables the Prediction of comorbid developments as well as the Determining optimal treatment pathways.
This close interlinking of intelligent data integration and molecular precision diagnostics marks the beginning of a new era of personalized medicine:
One
molecular symbiosis of proteomic diagnostics and individualized therapy.
January 2025
The German Society of Nephrology's newsletter presented the current status of clinically applicable biomarkers in the context of chronic kidney disease, focusing on early detection, prognosis, and differential diagnosis. Based on two recently published review articles by the UPTAKE consortium on non-invasive biomarkers for the treatment of patients with chronic kidney disease, the newsletter highlighted the prominent role of the diverse applications of Mosaiques' biomarkers and technology.
Both articles are available online in the "International Journal of Molecular Science" at https://www.mdpi.com/1422-0067/25/7/3678 or https://www.mdpi.com/1422-0067/25/6/3519 available.
December 2024
The European Commission has tasked an independent team of analysts with assessing the market potential of 13,000 innovations funded under the Horizon program. Among them, the urine diagnostic technology of proteomic analysis – used to determine the individual effect of drugs through in silico modeling – was recognized as "market-ready" and a "key innovation" with "high market creation potential".
You can find more information here.
November 2024
Executives of statutory health insurance funds and health policy experts from the Bundestag will meet on November 26, 2024, to discuss the topic with mosaiques/protexam. Future of the healthcare system to be discussed in Germany.
The molecular diagnosis and early detection of chronic diseases—the first of its kind—prevents organ damage and avoids pandemics like COVID-19, caused by SARS-CoV-2, and other viruses now emerging. Chronic diseases lead to damage to the endothelium (cells lining blood vessels) and scarring due to inflammation (fibrosis), which is associated with these chronic conditions and can result in severe cases of viral infections. This is the core focus of the health policy of Robert F. Kennedy Jr., the designated U.S. Secretary of Health and Human Services.
Proteomic analysis has proven its clinical value in well over 100 studies involving 1,200 renowned physicians and scientists, published in over 400 high-ranking scientific journals. Without proteomic analysis, no solution to this dilemma facing humanity is possible.
February 2024
The first statutory health insurance fund (The Innovation Fund) takes responsibility for its insured members and enables them to get tested by
protexam for the early detection of diseases. This helps in the prevention of chronic illnesses and cancer through the early application of appropriate therapies.